Andrew A. Hindman Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Andrew A. Hindman.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Andrew A. Hindman. Andrew A. Hindman is Chief Business Dev. Officer in ACORDA THERAPEUTICS INC ($ACOR) and Chief Business Officer in ACORDA THERAPEUTICS INC ($ACOR) and SVP, Chief Financial Officer in Theravance Biopharma, Inc. ($TBPH).
Latest Insider Trading Transactions of Andrew A. Hindman
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 10 2021 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Grant | A | 0.00 | 65,000 | 0 | 188,688 | 123.7 K to 188.7 K (+52.55 %) |
Aug 24 2020 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Payment of Exercise | F | 18.22 | 4,323 | 78,765 | 123,135 | 127.5 K to 123.1 K (-3.39 %) |
Jul 29 2020 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Grant | A | 0.00 | 20,000 | 0 | 127,458 | 107.5 K to 127.5 K (+18.61 %) |
Feb 24 2020 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Payment of Exercise | F | 25.90 | 7,060 | 182,854 | 106,490 | 113.6 K to 106.5 K (-6.22 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Grant | A | 0.00 | 20,000 | 0 | 113,550 | 93.6 K to 113.6 K (+21.38 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Grant | A | 0.00 | 43,550 | 0 | 93,550 | 50 K to 93.6 K (+87.10 %) |
Jul 03 2019 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Option Exercise | A | 16.94 | 260,000 | 4,404,400 | 260,000 | |
Jul 03 2019 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Grant | A | 0.00 | 50,000 | 0 | 50,000 | 0 to 50 K |
Mar 12 2019 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Offi ... | Option Exercise | A | 13.51 | 15,075 | 203,663 | 15,075 | |
Mar 12 2019 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Offi ... | Grant | A | 0.00 | 9,045 | 0 | 15,639 | 6.6 K to 15.6 K (+137.17 %) |
Feb 25 2019 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Offi ... | Payment of Exercise | F | 13.38 | 877 | 11,734 | 6,594 | 7.5 K to 6.6 K (-11.74 %) |
Dec 27 2018 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Offi ... | Grant | A | 0.00 | 2,300 | 0 | 7,471 | 5.2 K to 7.5 K (+44.48 %) |
Dec 06 2018 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Offi ... | Sell | S | 20.56 | 753 | 15,478 | 5,171 | 5.9 K to 5.2 K (-12.71 %) |
Nov 07 2018 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Offi ... | Payment of Exercise | F | 20.28 | 879 | 17,826 | 5,924 | 6.8 K to 5.9 K (-12.92 %) |
Sep 12 2018 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Offi ... | Grant | A | 0.00 | 2,300 | 0 | 6,803 | 4.5 K to 6.8 K (+51.08 %) |
May 30 2018 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Offi ... | Sell | S | 24.26 | 42,615 | 1,034,006 | 4,503 | 47.1 K to 4.5 K (-90.44 %) |
May 15 2018 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Offi ... | Payment of Exercise | F | 24.35 | 3,930 | 95,696 | 47,118 | 51 K to 47.1 K (-7.70 %) |
May 15 2018 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Offi ... | Payment of Exercise | F | 24.35 | 3,930 | 95,696 | 47,118 | 51 K to 47.1 K (-7.70 %) |
Feb 26 2018 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Grant | A | 0.00 | 5,742 | 0 | 51,048 | 45.3 K to 51 K (+12.67 %) |
Dec 05 2017 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Sell | S | 20.54 | 817 | 16,784 | 45,306 | 46.1 K to 45.3 K (-1.77 %) |
May 17 2017 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Sell | S | 15.75 | 7,704 | 121,319 | 46,123 | 53.8 K to 46.1 K (-14.31 %) |
May 03 2017 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Option Exercise | A | 16.50 | 65,000 | 1,072,500 | 65,000 | |
Mar 03 2017 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Option Exercise | A | 27.48 | 11,500 | 315,963 | 11,500 | |
Mar 03 2017 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Grant | A | 0.00 | 4,600 | 0 | 53,827 | 49.2 K to 53.8 K (+9.34 %) |
Dec 05 2016 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Sell | S | 20.72 | 443 | 9,180 | 49,227 | 49.7 K to 49.2 K (-0.89 %) |
May 16 2016 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Sell | S | 26.11 | 4,860 | 126,885 | 49,670 | 54.5 K to 49.7 K (-8.91 %) |
May 13 2016 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Option Exercise | A | 26.40 | 25,000 | 660,000 | 25,000 | |
Mar 04 2016 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Option Exercise | A | 35.53 | 26,796 | 952,062 | 26,796 | |
Dec 03 2015 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Sell | S | 38.26 | 442 | 16,911 | 54,530 | 55 K to 54.5 K (-0.80 %) |
May 15 2015 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Sell | S | 30.16 | 475 | 14,326 | 54,972 | 55.4 K to 55 K (-0.86 %) |
May 15 2015 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Sell | S | 29.78 | 4,304 | 128,168 | 55,447 | 59.8 K to 55.4 K (-7.20 %) |
Mar 06 2015 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Option Exercise | A | 35.74 | 23,885 | 853,650 | 23,885 | |
Mar 06 2015 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Grant | A | 0.00 | 4,215 | 0 | 59,751 | 55.5 K to 59.8 K (+7.59 %) |
Dec 31 2014 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Option Exercise | M | 41.07 | 25,000 | 1,026,750 | 25,000 | |
May 15 2014 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Option Exercise | A | 30.35 | 27,768 | 842,759 | 27,768 | |
May 15 2014 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Option Exercise | A | 30.35 | 138,840 | 4,213,794 | 138,840 | |
May 15 2014 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Grant | A | 0.00 | 9,256 | 0 | 55,536 | 46.3 K to 55.5 K (+20.00 %) |
May 15 2014 | ACOR | ACORDA THERAPEUTIC ... | Hindman Andrew A. | Chief Business Dev. ... | Grant | A | 0.00 | 46,280 | 0 | 46,280 | 0 to 46.3 K |
Page: 1